- Conditions
- Chronic Hepatitis B
- Interventions
- tenofovir DF, emtricitabine /tenofovir DF
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 10
- States / cities
- San Francisco, California • San Jose, California • Flushing, New York + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 145–168
of 340
matching trials from the live ClinicalTrials.gov search.
- Conditions
- HIV
- Interventions
- Tenofovir DF and Emtricitabine; Ritonavir-boosted Atazanavir
- Drug
- Lead sponsor
- Kenneth H. Mayer, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Acute HIV Infection
- Interventions
- VRC07-523LS, PGT121.414.LS, Placebo, ART
- Biological · Other · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Aurora, Colorado • Atlanta, Georgia + 6 more
- Conditions
- HIV Infection
- Interventions
- PCC, Emtricitabine/tenofovir (FTC/TDF (Truvada®))
- Behavioral · Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 15 Years to 17 Years · Male only
- Enrollment
- 78 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2016
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 3 more
- Conditions
- HIV Infections
- Interventions
- Tenofovir disoproxil
- Drug
- Lead sponsor
- Hennepin Healthcare Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 2
- States / cities
- Minneapolis, Minnesota
- Conditions
- HIV Infections
- Interventions
- Efavirenz, Emtricitabine/Tenofovir disoproxil fumarate
- Drug
- Lead sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Network
- Eligibility
- 16 Years and older · Female only
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 6
- States / cities
- San Diego, California • Boston, Massachusetts • St Louis, Missouri + 3 more
- Conditions
- HIV Infections, AIDS-Related Opportunistic Infections
- Interventions
- Emtricitabine/tenofovir disoproxil fumarate, Lopinavir/ritonavir, Stavudine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 13 Years and older
- Enrollment
- 283 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 43
- States / cities
- Sacramento, California • San Diego, California • San Francisco, California + 24 more
- Conditions
- HIV Infection
- Interventions
- Elvitegravir, Raltegravir, EVG placebo, RAL placebo, Background regimen
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 724 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 94
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 59 more
- Conditions
- HIV Infection
- Interventions
- Highly active antiretroviral therapy (HAART)
- Drug
- Lead sponsor
- International Maternal Pediatric Adolescent AIDS Clinical Trials Group
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,653 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 26
- States / cities
- Alhambra, California • Los Angeles, California • San Diego, California + 20 more
- Conditions
- HIV
- Interventions
- Emtricitabine, Tenofovir alafenamide, Tenofovir disoproxil
- Drug
- Lead sponsor
- CONRAD
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 73 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 2
- States / cities
- Pittsburgh, Pennsylvania • Norfolk, Virginia
- Conditions
- HIV Disease
- Interventions
- Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir)
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- HIV Infections
- Interventions
- atazanavir/cobicistat, darunavir/ritonavir dosage #1, darunavir/ritonavir dosage #2, darunavir/ritonavir dosage #3, elvitegravir/cobicistat, dolutegravir, tenofovir alafenamide fumarate (TAF), TAF w/cobicistat, TAF w/cobicistat or ritonavir, efavirenz, darunavir/cobicistat, lopinavir/ritonavir dosage #1, atazanavir/ritonavir/tenofovir dosage #1, rifampicin, ethambutol, isoniazid, pyrazinamide, kanamycin, amikacin, capreomycin, moxifloxacin, levoflaxacin, ofloxacin, ethionamide/prothionamide, terizidone/cycloserine, para-aminosalicylic acid (PAS), high dose INH, bedaquiline, clofazamine, delamanid, linezolid, pretomanid, ethinyl estradiol, etonogestrel implant, nevirapine, amprenavir, abacavir, lopinavir/ritonavir dosage #2, indinavir/ritonavir dosage #1, fosamprenavir/ritonavir, lopinavir/ritonavir dosage #3, atazanavir/ritonavir dosage #1, didanosine delayed release (Videx® EC), emtricitabine, tenofovir, nelfinavir dosage #1, tipranavir/ritonavir, lopinavir/ritonavir dosage #4, raltegravir, etravirine, maraviroc, atazanavir/ritonavir dosage #2, tenofovir/atazanavir/ritonavir dosage #2, nelfinavir dosage #2, indinavir/ritonavir dosage #2, rilpivirine, darunavir/ritonavir dosage #4
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Not listed
- Enrollment
- 1,578 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2020
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • La Jolla, California • Long Beach, California + 26 more
- Conditions
- Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis
- Interventions
- MK-8527, FTC/TDF, Placebo to MK-8527, Placebo to FTC/TDF
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 4,390 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 20 more
- Conditions
- HIV, HIV Infections
- Interventions
- Stribild, ATV, Ritonavir, FTC/TDF, Stribild Placebo, ATV Placebo, RTV Placebo, FTC/TDF Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 708 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 86
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 57 more
- Conditions
- Chronic Hepatitis B
- Interventions
- TDF, ADV, TDF placebo, ADV placebo, FTC/TDF
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 382 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2016
- U.S. locations
- 17
- States / cities
- La Jolla, California • Pasadena, California • San Diego, California + 12 more
- Conditions
- HIV-1-infection
- Interventions
- B/F/TAF
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 10
- States / cities
- Bakersfield, California • Palm Springs, California • San Diego, California + 7 more
- Conditions
- HIV Infections, ART, Noncompliance, Patient
- Interventions
- The Accelerate model of care, bictegravir/emtricitabine/tenofovir alafenamide 50/200/25 mg
- Other · Drug
- Lead sponsor
- University of Missouri-Columbia
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 4
- States / cities
- Columbia, Missouri • Kansas City, Missouri • Springfield, Missouri + 1 more
- Conditions
- HIV-1 Infection
- Interventions
- DTG, F/TAF, B/F/TAF, DTG Placebo, F/TAF Placebo, B/F/TAF Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 657 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 74
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 53 more
- Conditions
- HIV Infected
- Interventions
- Tenofovir, Emtricitabine, Atazanavir, Ritonavir
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 21 Years to 40 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- HIV Prevention
- Interventions
- LA-CAB, TDF/FTC
- Drug
- Lead sponsor
- Orlando Immunology Center
- Other
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 2 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- HIV-1-infection
- Interventions
- Bictegravir, Lenacapavir, B/F/TAF, Placebo to match B/F/TAF, Placebo to match BIC/LEN
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 577 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 51
- States / cities
- Phoenix, Arizona • Berkeley, California • Beverly Hills, California + 43 more
- Conditions
- HIV-1 Infection
- Interventions
- FTC/RPV/TAF, FTC/RPV/TDF Placebo, FTC/RPV/TDF, FTC/RPV/TAF Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 632 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 75
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 56 more
- Conditions
- Long Covid
- Interventions
- tenofovir disoproxil/emtricitabine, Selzentry, Placebo
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- HIV-1-infection
- Interventions
- B/F/TAF
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- Up to 120 Hours
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Atlanta, Georgia • Memphis, Tennessee